Tools

LEADER 02529cam 2200517 a 4500

001 ocm64445479;

003 OCoLC;

005 20141211185317.0;

008 060303s2006 dcua b f000 0 eng c;

020 a| 0160758777;

035 a| (Sirsi) o64445479;

035 a| (OCoLC)64445479;

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

074 a| 1038-A;

074 a| 1038-A (online);

074 a| 1038-B (MF);

074 a| 1038-B (online);

086 0 a| Y 4.F 49:S.PRT.109-45;

245 00 a| Committee staff report to the chairman and ranking member :b| review of the FDA's approval process for the vagus nerve stimulation therapy system for treatment-resistant depression /c| prepared by the staff of the Committee on Finance, United States Senate ; Charles E. Grassley, chairman, Max Baucus, ranking member.;

246 30 a| Review of the FDA's approval process for the vagus nerve stimulation therapy system for treatment-resistant depression;

260 a| Washington :b| U.S. G.P.O. :b| For sale by the Supt. of Docs., U.S. G.P.O.,c| 2006.;

300 a| iv, 386 pages :b| illustrations ;c| 24 cm.;

336 a| text2| rdacontent;

337 a| unmediated2| rdamedia;

338 a| volume2| rdacarrier;

490 1 a| S. prt ;v| 109-45;

500 a| At head of title: 109th Congress, 2d session, Committee print.;

500 a| "Printed for the use of the Committee on Finance.";

500 a| Distributed to some depository libraries in microfiche.;

500 a| Shipping list no.: 2006-0141-P.;

504 a| Includes bibliographical references.;

530 a| Also available via Internet from the Finance Committee web site. Address as of 4/27/06: http://finance.senate.gov/press/Gpress/02%5F2006%20report.pdf; current access available via PURL.;

610 10 a| United States.b| Food and Drug Administrationv| Rules and practice.=| ^A1253;

650 0 a| Vagus nerve.=| ^A5446;

830 0 a| S. prt.v| 109-45.=| ^A368658;

856 41 u| https://purl.fdlp.gov/GPO/LPS69295;

998 a| 1030426;

998 a| u1030426;

596 a| 1;

999 a| Y 4.F 49:S.PRT.109-45w| SUDOCc| 1i| 40372000280359d| 11/3/2008e| 10/29/2008l| JDOSm| JOYNERn| 1r| Ys| Yt| JDOSBKu| 3/28/2006x| BOOKz| JFEDDOCSo| .STAFF. 0;

Committee staff report to the chairman and ranking member : review of the FDA's approval process for the vagus nerve stimulation therapy system for treatment-resistant depression / prepared by the staff of the Committee on Finance, United States Senate ; Charles E. Grassley, chairman, Max Baucus, ranking member.

Other author	United States. Congress. Senate. Committee on Finance.
Format	Book
Publication Info	Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2006.
Description	iv, 386 pages : illustrations ; 24 cm.
Supplemental Content	https://purl.fdlp.gov/GPO/LPS69295
Subjects	United States. Food and Drug Administration--Rules and practice. Depression, Mental--Treatment. --Government policy. --United States. Transcutaneous electrical nerve stimulation--Therapeutic use. --Government policy. --United States. Vagus nerve.

Portion of title	Review of the FDA's approval process for the vagus nerve stimulation therapy system for treatment-resistant depression
Series	S. prt ; 109-45 S. prt. 109-45. ^A368658
General note	At head of title: 109th Congress, 2d session, Committee print.
General note	"Printed for the use of the Committee on Finance."
General note	Distributed to some depository libraries in microfiche.
General note	Shipping list no.: 2006-0141-P.
Bibliography note	Includes bibliographical references.
Other forms	Also available via Internet from the Finance Committee web site. Address as of 4/27/06: http://finance.senate.gov/press/Gpress/02%5F2006%20report.pdf; current access available via PURL.
ISBN	0160758777
GPO item number	1038-A
GPO item number	1038-A (online)
GPO item number	1038-B (MF)
GPO item number	1038-B (online)
Govt. docs number	Y 4.F 49:S.PRT.109-45

Availability

Library	Location	Call Number	Status	Item Actions
Joyner	Fed Docs Stacks	Y 4.F 49:S.PRT.109-45	✔ Available	Place Hold

Click here for more information about this title

Availability